We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    03795298
Previous Study | Return to List | Next Study

Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation (OPTION)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03795298
Recruitment Status : Active, not recruiting
First Posted : January 7, 2019
Last Update Posted : April 27, 2023
Information provided by (Responsible Party):
Boston Scientific Corporation

Brief Summary:
The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to oral anticoagulation following percutaneous catheter ablation for high risk patients with non-valvular atrial fibrillation.

Condition or disease Intervention/treatment Phase
Atrial Fibrillation Device: WATCHMAN FLX Implant Drug: Market-approved OAC Not Applicable

Detailed Description:

This study is a prospective, randomized, multi-center, global investigation to determine if left atrial appendage closure with the WATCHMAN FLX Device is a reasonable alternative to oral anticoagulation in patients after AF ablation.

A subject who signs informed consent is considered enrolled in the study. Subjects will be randomized to OAC or WATCHMAN FLX in equal fashion. Randomization will be stratified by sequential vs. concomitant planned ablation +/- WATCHMAN implantation, to help ensure balance of treatment assignments within the sequential and concomitant groups.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1600 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Comparison of Anticoagulation With Left Atrial Appendage Closure After AF Ablation
Actual Study Start Date : May 20, 2019
Estimated Primary Completion Date : November 2024
Estimated Study Completion Date : November 2024

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: WATCHMAN FLX
WATCHMAN FLX implant including modified post-implant drug regimen.
Device: WATCHMAN FLX Implant
Left atrial appendage closure with the WATCHMAN FLX device

Active Comparator: Market-approved OAC
Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.
Drug: Market-approved OAC
Used per IFU for atrial fibrillation stroke prevention for the duration of the trial.

Primary Outcome Measures :
  1. Stroke, all cause death, and systemic embolism [ Time Frame: 36 months ]
    WATCHMAN therapy is non-inferior for the occurrence of stroke (including ischemic and/or hemorrhagic), all cause death, and systemic embolism.

  2. Non-procedural bleeding [ Time Frame: 36 months ]
    WATCHMAN therapy is superior for non-procedural bleeding (ISTH major bleeding and clinically relevant non-major bleeding).

Secondary Outcome Measures :
  1. Major bleeding [ Time Frame: 36 months ]
    WATCHMAN therapy is non-inferior for ISTH major bleeding (including procedural bleeding).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. The subject is of legal age to participate in the study per the laws of their respective geography.
  2. Underwent a prior catheter ablation procedure for non-valvular AF between 90 and 180 days prior to randomization (sequential) or is planning to have clinically indicated catheter ablation within 10 days of randomization (concomitant).
  3. The subject has a calculated CHA2DS2-VASc score of 2 or greater for males or 3 or greater for females.
  4. The subject is deemed to be suitable for the defined protocol pharmacologic regimen.
  5. The subject is able to undergo TEE examinations.
  6. The subject or legal representative is able to understand and is willing to provide written informed consent to participate in the trial.
  7. The subject is able and willing to return for required follow-up visits and examinations.

Exclusion Criteria:

  1. The subject is currently enrolled in another investigational study that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance must be brought to the attention of the sponsor to determine eligibility, regardless of type of co-enrollment being proposed.
  2. The subject requires long-term anticoagulation therapy for reasons other than AF-related stroke risk reduction, for example due to an underlying hypercoagulable state (i.e., even if the device is implanted, the subjects would not be eligible to discontinue OAC due to other medical conditions requiring chronic OAC therapy).
  3. The subject is deemed by the treating physician to be unsuitable for chronic anticoagulation and/or aspirin therapy due to bleeding risk, allergy, or other reasons.
  4. The subject had or is planning to have any cardiac or major non-cardiac interventional or surgical procedure (excluding non-valvular AF ablation and cardioversion) within 30 days prior to or 60 days after randomization [including, but not limited to: percutaneous coronary intervention (PCI), other cardiac ablation (VT ablation, etc.), etc.].
  5. The subject had a stroke or transient ischemic attack (TIA) within the 60 days prior to randomization.
  6. The subject had a prior major bleeding event per ISTH definition within the 14 days prior to randomization. Lack of resolution of related clinical sequelae, or planned and pending interventions to resolve bleeding/bleeding source, are a further exclusion regardless of timing of the bleeding event.
  7. The subject has had a myocardial infarction (MI) documented in the clinical record as either a non-ST elevation MI (NSTEMI) or as an ST-elevation MI (STEMI), with or without intervention, within 90 days prior to randomization.
  8. The subject has a history of atrial septal repair or has an ASD/PFO device.
  9. The subject has an implanted mechanical valve prosthesis in any position.
  10. The subject is of childbearing potential and is, or plans to become pregnant during the time of the study (method of assessment upon study physician's discretion)
  11. The subject has a documented life expectancy of less than two years.
  12. The subject has a cardiac tumor.
  13. The subject has signs/symptoms of acute or chronic pericarditis.
  14. There is evidence of tamponade physiology.
  15. Contraindications (anatomical or medical) to percutaneous catheterization procedures.
  16. The subject has documented NYHA Class IV heart failure.
  17. The subject has documented surgical closure of the left atrial appendage.
  18. The subject has an active infection.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03795298

Show Show 116 study locations
Sponsors and Collaborators
Boston Scientific Corporation
Layout table for investigator information
Principal Investigator: Oussama Wazni, MD The Cleveland Clinic
Layout table for additonal information
Responsible Party: Boston Scientific Corporation
ClinicalTrials.gov Identifier: NCT03795298    
Other Study ID Numbers: S2239
First Posted: January 7, 2019    Key Record Dates
Last Update Posted: April 27, 2023
Last Verified: April 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
URL: http://www.bostonscientific.com/content/gwc/en-US/data-sharing-requests.html

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Keywords provided by Boston Scientific Corporation:
Non-valvular atrial fibrillation
Left atrial appendage
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes